Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead collaborate on an early-stage molecule that binds to a novel marker called ACP3.
BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem Read More »
Unos físicos han demostrado la existencia de una nueva forma de magnetismo que algún día podría aprovecharse para construir chips de memoria “espintrónica” más rápidos, más compactos y con menor consumo de energía. El …
Nueva forma de magnetismo observada por vez primera Read More »
¿Estamos solos en el universo? Esta antigua pregunta ha ocupado la mente de la humanidad durante mucho tiempo. En 1995, el descubrimiento del primer planeta de fuera de nuestro sistema solar, en órbita a una estrella similar al Sol, abrió una importante puerta a la exploraci&oac …
Kepler-725c, planeta rocoso gigante que podría ser habitable Read More »
The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into one.
After Axing Diabetes Asset, Vertex Lays Off 140 Staff Read More »
La contaminación acústica es un problema creciente en las ciudades que afecta tanto a la salud como al bienestar de los ciudadanos. Ante esta situación, un equipo de investigadores de la Universidad Politécnica de Madrid (UPM) en España ha llevado a cabo u …
Evalúan la capacidad de los muros verdes para absorber el ruido Read More »
The American Medical Association is also urging an “immediate reversal” of the HHS Secretary’s decision to oust all 17 members of the CDC’s vaccine advisory board.
AMA Calls for Senate Probe into RFK Jr. After Removal of CDC Vaccine Advisors Read More »
The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.
SpliceBio Nabs $135 Million Series B To Advance Protein Splicing Medicines Read More »
The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to develop long-acting versions of molecules against GLP-1 and other incretins.
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena Read More »
For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharma’s amylin efforts underwhelmed investors.
Novo Ups Obesity Ante With $800M+ Deep Apple Pact for Oral, Non-Incretin Drugs Read More »
Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions TPIP to be best-in-class in pulmonary arterial hypertension.
Insmed ‘Blows Away Expectations’ With Positive Data for Inhaled Hypertension Therapy Read More »
